In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic

G. M. Eliopoulos, S. Willey, E. Reiszner, P. G. Spitzer, G. Caputo, R. C. Moellering

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

The in vitro activity of LY 146032, a cyclic lipopeptide antibiotic belonging to the class of agents designated A21978C, was compared with those of vancomycin, cefpirome, cefotaxime, and clindamycin against selected gram-positive bacteria. The new drug inhibited all staphylococcal isolates, including methicillin-resistant strains, at concentrations of ≤1.0 μg/ml. The activity of LY 146032 was comparable to that of vancomycin against most streptococci, but the latter demonstrated greater potency against Streptococcus faecium and penicillin-resistant strains of pneumococci and viridans group streptococci. LY 146032 was markedly less active than vancomycin against Listeria monocytogenes (MICs for 90% of strains tested, 16 and 1.0 μg/ml, respectively). The activity of LY 146032 was enhanced as the concentration of calcium in the test medium was increased. MBCs were within eightfold of the MIC for each of 12 strains tested. In a rat model of enterococcal endocarditis, the administration of LY 146032 resulted in increased survival and a reduction in the bacterial titer within cardiac vegetations compared with untreated control animals.

Original languageEnglish (US)
Pages (from-to)532-535
Number of pages4
JournalAntimicrobial agents and chemotherapy
Volume30
Issue number4
DOIs
StatePublished - Jan 1 1986

Fingerprint

Daptomycin
Lipopeptides
Anti-Bacterial Agents
Vancomycin
cefpirome
Viridans Streptococci
Enterococcus faecium
Methicillin Resistance
Cefotaxime
Clindamycin
Listeria monocytogenes
Gram-Positive Bacteria
Streptococcus pneumoniae
Endocarditis
Streptococcus
Penicillins
In Vitro Techniques
Calcium
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Eliopoulos, G. M. ; Willey, S. ; Reiszner, E. ; Spitzer, P. G. ; Caputo, G. ; Moellering, R. C. / In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. In: Antimicrobial agents and chemotherapy. 1986 ; Vol. 30, No. 4. pp. 532-535.
@article{5e40600e927d4c788fd79dff6835b37c,
title = "In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic",
abstract = "The in vitro activity of LY 146032, a cyclic lipopeptide antibiotic belonging to the class of agents designated A21978C, was compared with those of vancomycin, cefpirome, cefotaxime, and clindamycin against selected gram-positive bacteria. The new drug inhibited all staphylococcal isolates, including methicillin-resistant strains, at concentrations of ≤1.0 μg/ml. The activity of LY 146032 was comparable to that of vancomycin against most streptococci, but the latter demonstrated greater potency against Streptococcus faecium and penicillin-resistant strains of pneumococci and viridans group streptococci. LY 146032 was markedly less active than vancomycin against Listeria monocytogenes (MICs for 90{\%} of strains tested, 16 and 1.0 μg/ml, respectively). The activity of LY 146032 was enhanced as the concentration of calcium in the test medium was increased. MBCs were within eightfold of the MIC for each of 12 strains tested. In a rat model of enterococcal endocarditis, the administration of LY 146032 resulted in increased survival and a reduction in the bacterial titer within cardiac vegetations compared with untreated control animals.",
author = "Eliopoulos, {G. M.} and S. Willey and E. Reiszner and Spitzer, {P. G.} and G. Caputo and Moellering, {R. C.}",
year = "1986",
month = "1",
day = "1",
doi = "10.1128/AAC.30.4.532",
language = "English (US)",
volume = "30",
pages = "532--535",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

Eliopoulos, GM, Willey, S, Reiszner, E, Spitzer, PG, Caputo, G & Moellering, RC 1986, 'In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic', Antimicrobial agents and chemotherapy, vol. 30, no. 4, pp. 532-535. https://doi.org/10.1128/AAC.30.4.532

In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. / Eliopoulos, G. M.; Willey, S.; Reiszner, E.; Spitzer, P. G.; Caputo, G.; Moellering, R. C.

In: Antimicrobial agents and chemotherapy, Vol. 30, No. 4, 01.01.1986, p. 532-535.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic

AU - Eliopoulos, G. M.

AU - Willey, S.

AU - Reiszner, E.

AU - Spitzer, P. G.

AU - Caputo, G.

AU - Moellering, R. C.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - The in vitro activity of LY 146032, a cyclic lipopeptide antibiotic belonging to the class of agents designated A21978C, was compared with those of vancomycin, cefpirome, cefotaxime, and clindamycin against selected gram-positive bacteria. The new drug inhibited all staphylococcal isolates, including methicillin-resistant strains, at concentrations of ≤1.0 μg/ml. The activity of LY 146032 was comparable to that of vancomycin against most streptococci, but the latter demonstrated greater potency against Streptococcus faecium and penicillin-resistant strains of pneumococci and viridans group streptococci. LY 146032 was markedly less active than vancomycin against Listeria monocytogenes (MICs for 90% of strains tested, 16 and 1.0 μg/ml, respectively). The activity of LY 146032 was enhanced as the concentration of calcium in the test medium was increased. MBCs were within eightfold of the MIC for each of 12 strains tested. In a rat model of enterococcal endocarditis, the administration of LY 146032 resulted in increased survival and a reduction in the bacterial titer within cardiac vegetations compared with untreated control animals.

AB - The in vitro activity of LY 146032, a cyclic lipopeptide antibiotic belonging to the class of agents designated A21978C, was compared with those of vancomycin, cefpirome, cefotaxime, and clindamycin against selected gram-positive bacteria. The new drug inhibited all staphylococcal isolates, including methicillin-resistant strains, at concentrations of ≤1.0 μg/ml. The activity of LY 146032 was comparable to that of vancomycin against most streptococci, but the latter demonstrated greater potency against Streptococcus faecium and penicillin-resistant strains of pneumococci and viridans group streptococci. LY 146032 was markedly less active than vancomycin against Listeria monocytogenes (MICs for 90% of strains tested, 16 and 1.0 μg/ml, respectively). The activity of LY 146032 was enhanced as the concentration of calcium in the test medium was increased. MBCs were within eightfold of the MIC for each of 12 strains tested. In a rat model of enterococcal endocarditis, the administration of LY 146032 resulted in increased survival and a reduction in the bacterial titer within cardiac vegetations compared with untreated control animals.

UR - http://www.scopus.com/inward/record.url?scp=0022469992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022469992&partnerID=8YFLogxK

U2 - 10.1128/AAC.30.4.532

DO - 10.1128/AAC.30.4.532

M3 - Article

C2 - 3024560

AN - SCOPUS:0022469992

VL - 30

SP - 532

EP - 535

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -